| Name | Title | Contact Details |
|---|---|---|
William Kachioff |
Chief Financial Officer | Profile |
David Cory |
Chief Executive Officer | Profile |
Stellar Biotechnologies is a world leader in the development and manufacture of keyhole limpet hemocyanin (KLH).
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.
Thrive Health Plans is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.